Therapeutic agents affecting the immune system and drug-induced inflammatory bowel disease (IBD): A review on etiological and pathogenetic aspects

Clin Immunol. 2022 Jan:234:108916. doi: 10.1016/j.clim.2021.108916. Epub 2021 Dec 29.

Abstract

In recent years, therapeutic agents affecting the immune system have been largely implemented in the treatment of various hematological, rheumatological and dermatological disorders. Their clinical use has offered important benefits for affected patients and has also ameliorated clinical outcome and prognosis in many cases. Nonetheless, as any treatment, the use of these drugs may be associated with side effects. One of the target organs in such cases is the gastrointestinal tract. In particular, the exacerbation or the onset of inflammatory bowel disease (IBD) in treated patients is not infrequent, although the mechanism of action of these agents may be different. In this review we will focus on the use of therapeutic agents affecting the immune system and the development or exacerbation of IBD, with a mention on the possible underlying pathogenetic mechanisms.

Keywords: Crohn's disease; Drugs; Inflammatory bowel disease; Ulcerative colitis.

Publication types

  • Review

MeSH terms

  • Humans
  • Immune Checkpoint Inhibitors / adverse effects
  • Immune System / drug effects*
  • Immunologic Factors / adverse effects
  • Inflammatory Bowel Diseases / chemically induced*
  • Interferons / adverse effects
  • Interleukins / antagonists & inhibitors
  • Isotretinoin / adverse effects
  • Protein-Tyrosine Kinases / antagonists & inhibitors
  • Rituximab / adverse effects
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors

Substances

  • Immune Checkpoint Inhibitors
  • Immunologic Factors
  • Interleukins
  • Tumor Necrosis Factor-alpha
  • Rituximab
  • Interferons
  • Protein-Tyrosine Kinases
  • Isotretinoin